Abstracts Archive - Page 469 of 2607 - ACR Meeting Abstracts

Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Oliver Distler¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Dinesh Khanna⁵, Kristin B Highland⁶, Gerrit Toenges⁷, Margarida Alves⁸ and Yannick Allanore⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
Abstract Number: 2550 • ACR Convergence 2023
The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
Zijing Yang¹, Maryam Adas¹, Bechman Katie¹, Deepak Nagra¹, Ali Soykan Uguzlar¹, Mark Russell¹, Nicky Wilson², Sophia Steer¹, Sam Norton¹ and James Galloway¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
Abstract Number: 2553 • ACR Convergence 2023
Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
Yanjie Hao¹, Dylan Hansen², Rangi Kandane-Rathnayake³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Jiacai Cho⁶, Aisha Lateef⁶, Laniyati Hamijoyo⁷, Shue-Fen Luo⁸, Yeong-Jian J Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Zhanguo Li¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Sang-Cheol Bae¹⁸, Fiona Goldblatt¹⁹, Sean O’Neill²⁰, Kristine Ng²¹, Annie Law²², BMDB Basnayake²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Cherica Tee²⁶, Michael Tee²⁶, Yoshiya Tanaka²⁷, Chak Sing Lau²⁸, Vera Golder³, Alberta Hoi²⁹, Eric Morand³⁰, Shereen Oon³¹ and Mandana Nikpour³², ¹The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹²University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁶Keio University School of Medicine, Tokyo, Japan, ¹⁷Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁸Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁹Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²⁰Department of Medicine, University of New South Wales, Kensington, Australia, ²¹Waitemata DHB, Auckland, New Zealand, ²²Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²³Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Middlemore Hospital, Auckland, New Zealand, ²⁶University of the Philippines, Manila, Philippines, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²⁹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³⁰Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³¹University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ³²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: There is increasing interest in adopting the principle of treating to target (T2T) in systemic lupus erythematosus (SLE). Remission and low disease activity states…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: 2535 • ACR Convergence 2023
Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management
Katherine Carpenter¹, Melissa French², Sarah Gilman³, Sara Johnson⁴, Patricia Castle⁴, S. Sam Lim⁵, Charmayne Dunlop-Thomas⁵, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Pro-Change Behavior Systems, Inc., Narragansett, RI, ⁵Emory University, Atlanta, GA
Background/Purpose: The Lupus Foundation of America (LFA) has engaged in a 5-year cooperative agreement with the Centers for Disease Control and Prevention to implement a…
Abstract Number: 2547 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
Cecile PHILIPPOTEAUX¹, Thibaut DELEPINE², Emeline Cailliau¹, Peggy Philippe¹, Nicolas TAISNE³, Tristan Pascart⁴, Julien Paccou¹, Bernard Cortet¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly⁵, ¹University Hospital Center of Lille, Lille, France, ²CHU de Lille, Lille University Hospital, Valenciennes, France, ³Valenciennes Hospital Center, Valenciennes, France, ⁴Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ⁵CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat (D2T) RA definition1, however, a definition of D2T axSpA is still lacking. To date, we have…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…
Abstract Number: 2574 • ACR Convergence 2023
Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Gabriela Martinez Zayas¹, David Karp¹ and Elena Joerns², ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…
Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
Abstract Number: 2440 • ACR Convergence 2023
Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis
Maria Gabriella Raimondo¹, Simon Rauber², Hashem Mohammadian³, Mario Angeli¹, Cong Xu¹, Aleix Rius Rigau⁴, Markus Luber¹, Hannah Labinsky⁵, Alina Ramming¹, Stefano Alivernini⁶, Jörg Distler¹, Ursula Fearon⁷, Douglas Veale⁸, Michael Sticherling⁹, Juan D Canete¹⁰, Georg Schett¹¹ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁶Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Trinity College Dublin, Dublin, Ireland, ⁸St.Vincent's University Hosp, Dublin, Ireland, ⁹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, ¹⁰Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Around 30% of the patients with psoriasis (PsO) develop psoriatic arthritis (PsA) overtime, suggesting the existence of a disease mediated skin-joint crosstalk. To date,…
Abstract Number: 2433 • ACR Convergence 2023
Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells
Gregg Silverman¹, William Rigby², Helena Jun¹, Jasmine Shwetar¹, Katie Tumang¹, Sergei Koralov³, Ellie Ivanova¹, David Mieles¹, Sladjana Skopelia-Gardner⁴ and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²Hitchcock-Dartmouth Medicine Center, Hanover, NH, ³NYU Grossman Schoolof Medicine, New York, NY, ⁴Hitchcock-Dartmouth Medicine Center, Lebanon, NH
Background/Purpose: Biologic agents of diverse molecular mechanisms of action are approved for RA, but we do not have a full understanding of the implications of…
Abstract Number: 2053 • ACR Convergence 2023
Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
Katherine Nowicki¹, Nathan Rogers², Carson Keeter², Nathan Donaldson², Jennifer Soep² and Yongdong (Dan) Zhao³, ¹University of Colorado, Lakewood, CO, ²University of Colorado, Aurora, CO, ³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is characterized by sterile inflammatory bone lesions and most commonly affects skeletally immature children. Non-steroidal anti-inflammatory drugs (NSAIDs) are the…
Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Naomi Patel¹, Aubree McMahon¹, Grace McMahon¹, Sebastian Perez-Espina¹, Isha Jha¹, Adam Jarvie¹ and John Stone², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
Abstract Number: 0329 • ACR Convergence 2023
Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study
Eike von Schlichting¹, Jan Dieris-Hirche², Imke Redeker³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²LWL-University Hospital, Department of Psychosomatic Medicine and Psychotherapy, Ruhr Universität Bochum, Bochum, Germany, ³Ruhr Universität Bochum, Bochum, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Mental health contributes to the morbidity of patients with inflammatory rheumatic musculoskeletal disease (iRMD). Despite extensive research conducted on the prevalence of depressive disorders,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].